Drug Topics

SEPTEMBER 10, 2022

In the early stages of development, researchers find 2 treatments are efficacious for diabetes.

197

197

STAT

SEPTEMBER 10, 2022

Earlier this year, a leading animal rights group asked U.S. authorities to investigate medical research labs for allegedly violating federal law after finding numerous instances where nearly 2,000 monkeys were shipped between facilities without required veterinary inspections. Now, the federal government appears to be acting.

145

145

Drug Topics

SEPTEMBER 10, 2022

Tips to help your pharmacy stand out as a knowledgeable CBD retailer.

Independent Pharmacies 212

Independent Pharmacies 212

STAT

SEPTEMBER 10, 2022

Alphabet’s life sciences offshoot Verily said Friday that it has raised $1 billion to fuel its next stage of development — one that will be steered by a new corporate leader as CEO Andy Conrad plans to shift to an advisory role. The eye-popping funding round was led by Alphabet, reinforcing Verily’s ties to its corporate parent even as it seeks to assert its independence and build a profitable business after years of sometimes scattershot projects and investments.

138

138

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

PharmExec

SEPTEMBER 10, 2022

FDA backs the benefits of adopting continuous manufacturing, a strategy which has accelerated approval and launch timelines, and its Emerging Technology Program could be a helpful tool.

FDA 130

FDA 130

STAT

SEPTEMBER 10, 2022

Home improvement retailer Home Depot and two other, smaller employers are appealing a recent $2.67 billion settlement that covers allegedly anticompetitive behavior from Blue Cross Blue Shield insurers. The appeals could potentially delay the release of the funds and the broader terms of the settlement, which U.S. District Judge R. David Proctor finalized in August.

Insurance 106

Insurance 106

STAT

SEPTEMBER 10, 2022

Eight years ago, a Dutch oncologist, John Haanen, set out to change melanoma treatment by arranging one of the largest and most rigorous trials ever for a cell therapy technique originally devised in the mid-’80s. He could not have picked worse timing.  Months after the trial began, European regulators approved the first PD-1 inhibitor, a groundbreaking immunotherapy.

98

98

PharmExec

SEPTEMBER 10, 2022

Our latest metrics tally across seven business-key measures uncovers some familiar players pacing the field in delivering shareholder value and getting the most from their investments.

59

59

STAT

SEPTEMBER 10, 2022

The brightest star in Boston’s rapidly growing biotech scene isn’t a flashy new player, but rather one of its longest standing companies. While many  biotech stocks have struggled this year  amid a broader economic downturn, Vertex Pharmaceuticals has risen 65 percent since its most recent low in October 2021. And the 33-year-old firm is now Boston’s most valuable biotech by a mile.

97

97

STAT

SEPTEMBER 10, 2022

WASHINGTON — Negotiations are intensifying over massive, multibillion-dollar legislation to fund the Food and Drug Administration, with just weeks left before the current agreement expires, four sources following the talks said. Democrats this week made a counteroffer to Republicans including Sen. Richard Burr (R-N.C.), who demanded in July that the so-called user fee bill pass without any additional health policy attached.

FDA 100

FDA 100

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA